The Healthcare Technology Report

Bringing Blind Spots Into Focus: Vasiliki (Vicky) Demas’ identifeye HEALTH Before she founded Identifeye HEALTH, Vicky Demas thought she’d spend her career refining magnetic resonance technology. Then a clinical trial changed her trajectory. The diagnostic tool she was working on flagged a rare fungal infection in time to save a patient’s life. That moment shifted her focus from engineering in theory to solving problems that could directly impact lives. In an interview with The Healthcare Technology Report, Demas walked through the experiences that led her to Identifeye. After a stint at Google X helping shape its life sciences initiatives, she became intrigued by the retina as a clinical tool. “That was a place that first actually introduced me to the concept of the retina and the power of the retina as a window not only to the soul, but also to the body and health,” she said. It’s rich with information about diabetes, cardiovascular risk, and early neurodegeneration—yet retinal exams remain rare outside of specialist settings. Most people simply never get one. Identifeye aims to change that.  The company is developing a handheld imaging device that anyone can operate, with automated guidance that removes the need for specialist training. Once captured, images are analyzed by machine learning models trained to flag signs of disease. The technology is already being prepared for rollout in primary care clinics and pharmacies—settings where early detection matters but time and expertise are limited. “We’re preparing to enter the market,” she told The Healthcare Technology Report, “Eventually, this can be a stand-alone. You can imagine at your gym, et cetera, but we're starting with primary care settings, pharmacies, potentially, retail clinics, and so forth.” With a 40-person team spanning engineering, clinical ops, and commercial infrastructure, Identifeye is scaling up. Investors include Foresite Capital, Glenview Capital Management, and Hildred, and another raise is planned for later this year. Initial efforts focus on diabetic retinopathy, but the broader aim is to embed retinal data into the foundation of preventative care. Being a first-time CEO brings its own challenges. “Everything ends with you,” she said. “You have all the responsibility, sometimes not all of the control.” But she stays focused by trusting her team and believing in the mission. For Demas, the next step is clear: make preventative care easier to access, and harder to ignore.

Williams-Sonoma, Inc. and No Kid Hungry Launch Annual Anti-Hunger Campaign in America with Celebrities and Chefs To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #retail #nonprofit #donation #antihunger #campaign https://xmrrwallet.com/cmx.plnkd.in/e8risSy8

Tebra and WoundZoom Partner to Streamline Wound Care for Practices To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #software https://xmrrwallet.com/cmx.plnkd.in/eku5uHse

How DoseMe CEO Paul Edwards is Helping Doctors Dose Smarter When Paul Edwards, the President and Chief Executive Officer of DoseMe, first started working in the medical space, he was struck by the difficulties in using antibiotics to treat patients. “You had these very powerful antibiotics that you knew you couldn't let everybody use,” he said in a 2024 interview, “but at the same time, a physician, because he knew so little about what was happening with the patient, would obviously always choose that big gun antibiotic.” What Edwards realized was that doctors needed to dose smarter, which is the guiding principle behind DoseMe, which he’s run since 2023. In a world where drug development is happening faster and more aggressively than ever, Edwards is working to make sure those drugs are identified and administered to the patients for whom they’re intended, rather than leaving physicians to play guessing games. He analogizes DoseMe’s process to someone attending a sporting event. Broadly speaking, you know where the stadium is, not unlike a doctor would, broadly speaking, be able to identify what could be wrong with a patient. But just as someone attending a football game would need to find their specific seat, DoseMe is designed to help a physician find precisely the right antibiotic with which to treat the patient. DoseMe uses population-based modeling to do this, looking at several medical criteria – age, weight, ethnicity – in conjunction with a Bayesian statistical model, which “gives the clinician very precise information about what dose and for how long and how many times.” By so doing, DoseMe helps speed up every part of the often laborious process of receiving medical treatment, a timesaving effort with a long tail, especially when it comes to vancomycin, a drug used to treat specific bacterial infections. “If you're using trough-based dosing for vancomycin, you need to take blood levels probably every 12 to 24 hours,” Edwards said.”If you're using Bayesian dosing, you take one blood level. You don't take another one. So you're saving on nursing time, you're saving on pharmacy time, and you're getting to your correct dose, your precise dose quicker than you would do with a trough-based dosing methodology, which is what we've used for 30, 40, 50 years.” In enabling doctors to do their best work, Edwards is living his creed. He believes in surrounding himself with smart people and letting them shine – and, critically, he knows when to “get out of the way and let them do what they're good at.” 

Aidoc receives $40 million in debt funding and $110 million in funding from WellSpan Health, Sutter Health, Square Peg Venture Capital Ltd. ,nVentures, Mercy, Hartford HealthCare, and General Catalyst. Aidoc assists physicians in clinical decisions for over 45 million patients a year, helping health systems deliver smarter and faster care when it matters most. Its mission is to transform patient outcomes through "always on" clinical AI, eliminating preventable care gaps that lead to loss of lives and disabilities. To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #venturecapital #clinical #physicians

AbbVie and IGI Sign Global Deal for Trispecific Antibody ISB 2001 To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #pharmaceuticals #biotechnology https://xmrrwallet.com/cmx.plnkd.in/grTxFV-Z

Moderna Gets FDA Approval for Spikevax in Young Children To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #biotechnology #pharmaceuticals #vaccine https://xmrrwallet.com/cmx.plnkd.in/grGUtMSi

Ambience Healthcare receives $243 million in funding from Town Hall Ventures, Smash Capital, Optum Ventures, OpenAI Startup Fund, Oak HC/FT, Kleiner Perkins, Georgian, Frist Cressey Ventures, Founders Circle Capital, and Andreessen Horowitz. Ambience Healthcare is the leading AI platform for documentation, coding, and clinical workflow, built to reduce administrative burden and protect revenue integrity at the point of care. To nominate for Top 100 Healthcare Technology Companies of 2025, click here: https://xmrrwallet.com/cmx.plnkd.in/g_SjH_kp Sign up for our free email newsletter at https://xmrrwallet.com/cmx.plnkd.in/gNfBS6g #healthtech #healthcare #venturecapital #ai #platform

Hala Borno Wants Precision Medicine to Reach Everyone Hala Borno arrived in the U.S. as a refugee of the first Gulf War. She learned English as a second language, navigated the healthcare system alongside her mother during her grandfather’s cancer treatment, and grew up acutely aware of the barriers facing vulnerable communities. She’s spent her career confronting structural gaps in care, first as a physician, then as a researcher, and now as the founder of Trial Library, a company working to dismantle one of the most entrenched inequities in medicine: who gets access to clinical trials. Despite making up the majority of cancer patients in the U.S., people treated in community settings are rarely enrolled in oncology trials. Most research still runs through academic centers, excluding many patients, especially ethnic minorities and underserved populations, from the benefits of precision medicine. “We are at a point in cancer precision medicine where we are seeing miraculous responses to targeted therapies,” Borno has said. “Unfortunately, we are still leaving many patients behind.” Trial Library, launched in 2021 with support from UCSF Innovation Ventures, is built to change that. The platform equips providers with tools to identify relevant trials at the point of care and offers AI-powered navigation to support patients through enrollment. That navigation is designed to surface and address social determinants of health—a core focus of Borno’s academic research. Borno reached out to more than 800 community oncologists across California to understand what was standing in the way. Through those conversations, she recognized that prescreening needed to be worth a physician’s time. Trial Library addressed this by offering sponsor-funded reimbursements to providers—an operational shift that made trial participation more feasible. “Our model is very thoughtful,” Borno explained. “What are the barriers for the medical provider? For the patient?” Today, Trial Library connects more than 1,500 providers across 320 clinics. Borno still holds her role as Associate Professor of Medicine at UCSF, where she has published over 100 peer-reviewed papers and served in leadership roles focused on health equity and community engagement. Her decision to leave academia and build a venture-backed company didn’t come quickly, but it didn’t go away either. “Listen to that hum in the back of your mind,” she’s said. “If it doesn’t go away, do something.” And do something she did.

Leslie Orne Was Headed to Stanford. She Helped Build a Life Sciences Powerhouse Instead. Leslie Orne was packed for Stanford. She’d been accepted to the MBA program and was ready to head west until a conversation with Trinity Life Sciences’ founder changed the plan. “At the last minute the founder of Trinity convinced me to stay and grow the business,” she said. “Here we are today as one of the leading commercial partners to life sciences companies.” That single decision set her on a decades-long path inside Trinity. Orne joined in 2001 as an associate consultant. She’s now CEO of a 1,300-person firm with 12 offices and more than 350 active clients. Along the way, she’s been behind billions in strategic transactions, dozens of drug launches, five acquisitions, and a partnership with Bain & Company. But none of this was preordained. “It is okay to pivot,” Orne has said. “Be open minded—the path won’t always be straight.” Case in point: When she became CEO, she put together a detailed 90-day plan, typical of her years in consulting. Then she scrapped it. The plan was too complex, the timeline too rigid. Instead, she spent her first three months listening—to employees, clients, and the market before making her next move. Orne defines effective leadership as stepping up, offering solutions, and giving people the freedom to own their work. “Lead by example. If you wouldn’t do it, why would they?” she’s said. “Encourage those around you to constantly learn, and to be smarter than you are.” The title doesn’t change who she is, she says: “CEOs are normal people too.” She still watches The Bachelor and listens to Taylor Swift. But the work carries weight. “At Trinity, we live our purpose every day – Every Decision Impacts a Life.”